We need a new CEO, and we need a new CEO now.
If Resolute can raise $45M, there is no reason CYDY should not be able to do so.
After all, RZLT was at .11, and on the verge of bankruptcy, when it got big money from Korean institutions on terms that were much less dilutive than the bad deals made by Pourhassan for CYDY.
Good management is the key to success for most companies, and that is especially true of clinical stage biopharmas.
If CYDY had a competent CEO, the company would flourish, and the SP would soar.
It is bewildering that the BOD would not only keep Pourhassan on as CEO, but approve a salary befitting a CEO with a long and distinguished record of success.
We can do better, much better, than Nader Pourhassan.
BOD: Are you watching and listening?
LM
News 
Market Data 
Discover 
